Skip to main content

Table 4 iBox variables

From: Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

  1. DSA Donor-specific antibodies, eGFR Estimated glomerular filtration rate, MFI Mean fluorescence intensity
Back to article page

Trials

ISSN: 1745-6215